Autoimmunity
- Biotech or pharma, therapeutic R&D
ABS is a seed stage biotech company developing both precision therapies and diagnostics to address a large, genetically defined subset of patients with autoimmune disease who respond poorly if at all to existing standards of care.
Approximately 50% of patients with autoimmune disease have a SNP that upregulates soluble IL7 receptor (sIL7R) up to three-fold. Elevated sIL7R has been associated with poor outcomes in numerous autoimmune diseases. Examples include: higher risk of progressive disease (e.g., Multiple Sclerosis); more severe disease (e.g., Lupus Nephritis), and poor response to therapy (e.g., Rheumatoid Arthritis). sIL7R acts as an agonist to IL7 (by ligand stabilization, like sIL4R and sIL15R), leading to highly amplified autoreactive T cell activation and proliferation, resulting in the clinical consequences listed above.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}